← Back to Search

Lumason® for Liver Cancer

Q: What is the cap for participant intake for this research study?

<p>Affirmative. Per the data on clinicaltrials.gov, this trial is actively recruiting patients with initial postings from February 19th 2020 and last updated November 2nd 2022. The project will recruit 25 individuals at a single site.</p>

Q: Are there still opportunities to volunteer for this experiment?

<p>This clinical trial is currently in search of volunteers; the initial posting was launched on February 19th 2020 and amended most recently on November 2nd 2022.</p>

Phase < 1

Waitlist Available

Led By Melissa McGettigan, MD

Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up base line up to 24 weeks

Awards & highlights

Study Summary

This trial is testing if Lumason microbubbles can help people with liver lesions by either helping determine an early response to radioembolization or demonstrating radiation toxicity to the surrounding liver.

Eligible Conditions

Liver Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ base line up to 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~base line up to 24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and base line up to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants with Early Tumor Response

Secondary outcome measures

Number of Participants with Early Signs of Radiation Induced Liver Disease (RILD)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Lumason MicrobubblesExperimental Treatment1 Intervention

Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor

542 Previous Clinical Trials

135,488 Total Patients Enrolled

6 Trials studying Liver Cancer

101 Patients Enrolled for Liver Cancer

Melissa McGettigan, MDPrincipal InvestigatorMoffitt Cancer Center

Jennifer Sweeney, MDPrincipal InvestigatorMoffitt Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap for participant intake for this research study?

"Affirmative. Per the data on clinicaltrials.gov, this trial is actively recruiting patients with initial postings from February 19th 2020 and last updated November 2nd 2022. The project will recruit 25 individuals at a single site."

Answered by AI

Are there still opportunities to volunteer for this experiment?

"This clinical trial is currently in search of volunteers; the initial posting was launched on February 19th 2020 and amended most recently on November 2nd 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

2020. "Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04150874.